• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SVP & CHIEF FINANCIAL OFFICER Sawaf Aziz covered exercise/tax liability with 9,348 units of Ordinary Shares, decreasing direct ownership by 2% to 364,790 units (SEC Form 4)

    5/22/25 6:42:52 PM ET
    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TBPH alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Sawaf Aziz

    (Last) (First) (Middle)
    C/O THERAVANCE BIOPHARMA US, LLC
    901 GATEWAY BLVD

    (Street)
    SOUTH SAN FRANCISCO CA 94080

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Theravance Biopharma, Inc. [ TBPH ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    SVP & CHIEF FINANCIAL OFFICER
    3. Date of Earliest Transaction (Month/Day/Year)
    05/20/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Ordinary Shares 05/20/2025 F 9,348(1) D $9.45 364,790 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.
    /s/ Brett A. Grimaud, Attorney-in-Fact 05/22/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $TBPH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TBPH

    DatePrice TargetRatingAnalyst
    8/6/2024$15.00 → $10.00Outperform → Market Perform
    Leerink Partners
    4/12/2024$21.00Buy
    BTIG Research
    1/8/2024Outperform → In-line
    Evercore ISI
    5/23/2022$12.00Outperform
    SVB Leerink
    3/2/2022$10.00 → $11.00Underweight
    Morgan Stanley
    2/24/2022$8.00 → $12.00Buy
    HC Wainwright & Co.
    11/5/2021$7.00 → $12.00Underweight → Neutral
    JP Morgan
    9/16/2021$14.00 → $10.00Underweight
    Morgan Stanley
    More analyst ratings

    $TBPH
    SEC Filings

    See more
    • Theravance Biopharma Inc. filed SEC Form 8-K: Other Events

      8-K - Theravance Biopharma, Inc. (0001583107) (Filer)

      6/6/25 6:03:07 AM ET
      $TBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Theravance Biopharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Theravance Biopharma, Inc. (0001583107) (Filer)

      6/2/25 6:02:21 AM ET
      $TBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Theravance Biopharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Theravance Biopharma, Inc. (0001583107) (Filer)

      5/20/25 5:00:27 PM ET
      $TBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TBPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Theravance Biopharma downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded Theravance Biopharma from Outperform to Market Perform and set a new price target of $10.00 from $15.00 previously

      8/6/24 8:00:45 AM ET
      $TBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG Research initiated coverage on Theravance Biopharma with a new price target

      BTIG Research initiated coverage of Theravance Biopharma with a rating of Buy and set a new price target of $21.00

      4/12/24 7:40:50 AM ET
      $TBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Theravance Biopharma downgraded by Evercore ISI

      Evercore ISI downgraded Theravance Biopharma from Outperform to In-line

      1/8/24 8:38:16 AM ET
      $TBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care